← Leaderboards
Christine M. Lovly
Vanderbilt University
$3,238,974
Attributed
$4,111,460
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $667.4K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,111,460 · 3
VA$0 · 1
By mechanism
R01$2,647,610 · 2
P01$1,463,850 · 1
I01$0 · 1
Top collaborators
- Jens Meiler7 shared
- Ann Richmond1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Ann Richmond$15,857,391
- Sebastian Joyce$13,492,547
- John Tanner Wilson$7,006,172
- Todd D Giorgio$1,175,390
- Raymond Nelson Dubois$22,706,669
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationTumorInsightEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorTherapeutic TargetEpidermal Growth Factor ReceptorPhosphotransferasesMediatingMalignant Neoplasm Of LungMolecularRecurrenceBiochemicalStandard Of CareCellsInnovationFda ApprovedChimeric ProteinsSignal TransductionGenomicsLung AdenocarcinomaExonsLung NeoplasmsPre-Clinical ModelBase
Grant awards (16)
Combining Immune Therapy with Targeted Therapies to Improve Melanoma Survival$0
I01 · FY2025 · VA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$316,483
R01 · FY2023 · CA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$15,047
R01 · FY2023 · CA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$319,598
R01 · FY2022 · CA · contact PI
Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer$297,024
P01 · FY2022 · CA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$50,818
R01 · FY2022 · CA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$343,923
R01 · FY2021 · CA · contact PI
Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer$303,085
P01 · FY2021 · CA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$346,920
R01 · FY2020 · CA · contact PI
Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer$303,085
P01 · FY2020 · CA · contact PI
Mechanistic insights into Variants of Uncertain Significance (VUS) using novel EGFR variants as a paradigm$352,184
R01 · FY2019 · CA · contact PI
Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer$266,261
P01 · FY2019 · CA · contact PI
Project 3: Mechanisms and Modulators of Sensitivity and Resistance to Kinase Inhibitors in Lung Cancer$294,395
P01 · FY2018 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$306,119
R01 · FY2016 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$302,801
R01 · FY2015 · CA · contact PI
Overcoming acquired resistance to EGFR inhibitors in lung cancer$293,717
R01 · FY2014 · CA · contact PI